Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial-Reference-Cited by-同舟云学术

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Published:2021-02-25 Issue:7 Volume:11 Page:1688-1699
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Riely Gregory J.,Neal Joel W.^ORCID,Camidge D. Ross,Spira Alexander I.,Piotrowska Zofia,Costa Daniel B.,Tsao Anne S.^ORCID,Patel Jyoti D.,Gadgeel Shirish M.,Bazhenova Lyudmila^ORCID,Zhu Viola W.,West Howard L.,Mekhail Tarek,Gentzler Ryan D.^ORCID,Nguyen Danny^ORCID,Vincent Sylvie^ORCID,Zhang Steven,Lin Jianchang,Bunn Veronica,Jin Shu^ORCID,Li Shuanglian,Jänne Pasi A.

Funder

NCI

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 177 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen;Lung Cancer;2024-09

2. Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer;European Journal of Cancer;2024-09

3. A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations;International Journal of Clinical Oncology;2024-08-27

4. Drug development and evidence for lung cancer targeted therapy in Eastern Asia;The Lancet Regional Health - Western Pacific;2024-08

5. Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non–Small Cell Lung Cancer: Single-Institution Experience;Cancer Research and Treatment;2024-07-15